UEEC's Losses Mount Amid Zero Revenue, Cash Dwindles

TL;DR

**UEEC is burning cash with no revenue, making it a highly speculative bet on future regulatory approval and financing.**

AI Summary

United Health Products, Inc. (UEEC) reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company experienced a significant increase in net loss, reaching $2,132,440 for the nine months ended September 30, 2025, up from $1,187,621 in the same period of 2024, representing a 79.5% increase. This was primarily driven by a substantial rise in selling, general, and administrative expenses to $1,768,183 for the nine months ended September 30, 2025, compared to $975,017 in 2024, and increased interest expenses. Cash and cash equivalents plummeted to $18,376 as of September 30, 2025, from $168,883 at December 31, 2024. The company's total liabilities grew to $3,433,856 from $2,713,810, while total assets decreased to $94,313 from $269,979. A 'going concern' warning was issued due to recurring net losses, negative working capital, and insufficient revenue to cover operating expenses, with future funding reliant on equity sales and traditional financing. The company continues to develop its CelluSTAT hemostatic gauze and is seeking regulatory approval for the U.S. Class III human surgical markets.

Why It Matters

This filing reveals a company in a precarious financial state, with zero revenue and rapidly increasing losses, which is a critical red flag for investors. The 'going concern' warning explicitly states the company's inability to cover operating expenses, indicating a high risk of financial distress or even bankruptcy if new funding isn't secured. For employees, this signals potential job insecurity, while customers and the broader market face uncertainty regarding the future availability of its CelluSTAT product. Competitively, without revenue, UEEC is falling further behind established medical device companies, struggling to bring its patented product to market effectively.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to 'recurring net losses, negative working capital and operations have not provided cash flows.' Cash and cash equivalents dropped from $168,883 at December 31, 2024, to $18,376 by September 30, 2025, a 89.1% decrease, while net loss for the nine months ended September 30, 2025, was $2,132,440 with no revenue.

Analyst Insight

Investors should avoid UEEC given the severe 'going concern' risk, zero revenue, and rapidly depleting cash reserves. Any investment would be highly speculative, contingent on successful regulatory approval for CelluSTAT and securing substantial new financing, both of which are uncertain.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$94,313

total Debt

$3,433,856

net Income

-$2,132,440

eps

N/A

gross Margin

N/A

cash Position

$18,376

revenue Growth

N/A

Key Numbers

• $0 — Revenue (for the three and nine months ended September 30, 2025, indicating no sales)
• $2,132,440 — Net Loss (for the nine months ended September 30, 2025, a 79.5% increase from prior year)
• $18,376 — Cash and Cash Equivalents (as of September 30, 2025, down 89.1% from December 31, 2024)
• $3,339,543 — Total Stockholders' Deficit (as of September 30, 2025, worsening from $2,443,831 at December 31, 2024)
• $1,768,183 — Selling, General and Administrative Expenses (for the nine months ended September 30, 2025, a significant increase from $975,017 in 2024)

Key Players & Entities

• United Health Products, Inc. (company) — developer, manufacturer, and marketer of CelluSTAT hemostatic gauze
• CelluSTAT (product) — patented hemostatic gauze product
• SEC (regulator) — Securities and Exchange Commission
• $2,132,440 (dollar_amount) — net loss for the nine months ended September 30, 2025
• $1,187,621 (dollar_amount) — net loss for the nine months ended September 30, 2024
• $18,376 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $168,883 (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $3,433,856 (dollar_amount) — total liabilities as of September 30, 2025
• $94,313 (dollar_amount) — total assets as of September 30, 2025
• Chief Executive Officer (person) — Company's chief operating decision maker (CODM)

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to recurring net losses, negative working capital, and insufficient revenue to cover operating expenses. Future funding is heavily reliant on equity sales and traditional financing, which are not guaranteed.
• Deteriorating Financial Position [high — financial]: Total liabilities increased to $3,433,856 as of September 30, 2025, from $2,713,810 at December 31, 2024, while total assets decreased to $94,313 from $269,979. This significant asset decline and liability increase points to a rapidly worsening financial health.
• Plummeting Cash Reserves [high — financial]: Cash and cash equivalents have drastically fallen to $18,376 as of September 30, 2025, a 89.1% decrease from $168,883 at December 31, 2024. This low cash balance poses an immediate liquidity risk.
• Lack of Revenue Generation [high — operational]: The company reported zero revenue for the three and nine months ended September 30, 2025, mirroring the prior year. This persistent lack of sales indicates a fundamental challenge in commercializing its products or generating market demand.
• Escalating Operating Expenses [high — operational]: Selling, General, and Administrative (SG&A) expenses surged to $1,768,183 for the nine months ended September 30, 2025, from $975,017 in the same period of 2024, a substantial increase of 81.3%. This rise in costs, without corresponding revenue, exacerbates net losses.
• Regulatory Approval Dependency [high — regulatory]: The company's future success is contingent on obtaining regulatory approval for its CelluSTAT hemostatic gauze for U.S. Class III human surgical markets. Delays or failure to secure these approvals will prevent market entry and revenue generation.

Industry Context

The medical device industry, particularly for surgical products, is highly competitive and heavily regulated. Companies like UEEC must navigate complex approval processes (e.g., FDA Class III) and demonstrate clinical efficacy and safety to gain market traction. Success often hinges on innovation, strong clinical data, and effective sales and distribution channels.

Regulatory Implications

UEEC's reliance on regulatory approval for its CelluSTAT product presents a significant hurdle. Obtaining FDA Class III clearance is a rigorous and time-consuming process that requires substantial investment and can result in delays or outright rejection, directly impacting the company's revenue potential.

What Investors Should Do

1. Monitor cash burn and future financing rounds.
2. Evaluate progress on regulatory approval for CelluSTAT.
3. Assess the sustainability of SG&A expenses.

Key Dates

• 2025-09-30: End of Nine Months Reporting Period — Reported zero revenue, a net loss of $2,132,440, and cash reserves of $18,376, highlighting severe financial distress and a going concern warning.
• 2024-09-30: Prior Year Nine Months Reporting Period — Reported zero revenue and a net loss of $1,187,621, providing a baseline for the significant deterioration in financial performance observed in 2025.
• 2024-12-31: Prior Year End Reporting Period — Reported cash and cash equivalents of $168,883 and total liabilities of $2,713,810, serving as a comparison point for the sharp decline in liquidity and increase in liabilities by September 30, 2025.

Glossary

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (UEEC has received a 'going concern' warning, indicating serious doubts about its ability to continue operations without further financing.)

Working Capital

The difference between a company's current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations. (UEEC has negative working capital, meaning its short-term liabilities exceed its short-term assets, contributing to the going concern warning.)

Class III Medical Device

A category of medical devices that are considered high-risk and require the most stringent regulatory controls from agencies like the FDA to ensure safety and effectiveness. (UEEC is seeking approval for its CelluSTAT product in this category, indicating a complex and lengthy regulatory pathway.)

Hemostatic Gauze

A type of medical dressing designed to stop bleeding quickly by promoting blood clotting. (This is the primary product UEEC is developing, and its market success is critical for the company's survival.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, United Health Products, Inc. (UEEC) has seen a dramatic worsening of its financial condition. Revenue remains at $0, but the net loss has increased by 79.5% to $2,132,440, driven by a significant 81.3% surge in SG&A expenses to $1,768,183. Liquidity has evaporated, with cash and cash equivalents plummeting by 89.1% to $18,376, while total liabilities have grown substantially, leading to a severe going concern risk.

Filing Documents

• ueec_10q.htm (10-Q) — 697KB
• ueec_311.htm (EX-31.1) — 9KB
• ueec_312.htm (EX-31.2) — 9KB
• ueec_321.htm (EX-32.1) — 4KB
• ueec_322.htm (EX-32.2) — 4KB
• 0001477932-25-008280.txt ( ) — 3359KB
• ueec-20250930.xsd (EX-101.SCH) — 36KB
• ueec-20250930_lab.xml (EX-101.LAB) — 240KB
• ueec-20250930_cal.xml (EX-101.CAL) — 35KB
• ueec-20250930_pre.xml (EX-101.PRE) — 190KB
• ueec-20250930_def.xml (EX-101.DEF) — 94KB
• ueec_10q_htm.xml (XML) — 395KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2025 and September 30, 2024 (unaudited) 4 Condensed Statement of Stockholders' Deficiency for the Three and Nine Months Ended September 30, 2025 and September 30, 2024 (unaudited) 5 Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2025 and September 30, 2024 (unaudited) 7 Notes to Condensed Financial Statements (unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures

Quantitative and Qualitative Disclosures 27 Item 4.

Controls and Procedures

Controls and Procedures 27

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29

SIGNATURES

SIGNATURES 30 2 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Balance Sheets September 30, December 31, 2025 2024 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 18,376 $ 168,883 Prepaid and other current assets 24,753 22,800 Total current assets 43,129 191,683 Operating lease right-of-use asset 23,021 47,096 Security deposit 2,850 2,850 Patents, net 25,313 28,350 TOTAL ASSETS $ 94,313 $ 269,979 Current Liabilities Accounts payable and accrued expenses $ 1,065,293 $ 830,672 Accrued liabilities - related parties 233,842 168,649 Accrued compensation 683,267 608,500 Operating lease liability - current 23,954 33,331 Total current liabilities 2,006,356 1,641,152 Convertible notes payable, net of debt discount 927,500 557,500 Convertible notes payable – related party, net of debt discount 500,000 500,000 Operating lease liability – long-term - 15,158 TOTAL LIABILITIES 3,433,856 2,713,810 Commitments and Contingencies - - Stockholders' Deficit Series A Convertible Preferred Stock - $ 0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding - - Common Stock - $ 0.001 par value, 300,000,000 shares Authorized, 258,690,253 and 252,408,222 shares issued and outstanding at September 30, 2025 and December 31, 2024 258,690 252,408 Subscription Receivable - - Additional Paid-In Capital 77,235,150 76,004,704 Accumulated Deficit ( 80,833,383 ) ( 78,700,943 ) Total Stockholders' Deficit ( 3,339,543 ) ( 2,443,831 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 94,313 $ 269,979 See notes to unaudited condensed financial statements. 3 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Statements of Operations (Unaudited) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2025 2024 2025 2024 Revenues $ - $ - $ - $ - Opera

View Full Filing

View this 10-Q filing on SEC EDGAR